Safety, tolerability, and risks associated with first-and second-generation antipsychotics: a state-of-the-art clinical review
M Solmi, A Murru, I Pacchiarotti… - … and clinical risk …, 2017 - Taylor & Francis
Since the discovery of chlorpromazine (CPZ) in 1952, first-generation antipsychotics (FGAs)
have revolutionized psychiatric care in terms of facilitating discharge from hospital and …
have revolutionized psychiatric care in terms of facilitating discharge from hospital and …
[HTML][HTML] Schizophrenia: overview and treatment options
KR Patel, J Cherian, K Gohil… - Pharmacy and …, 2014 - ncbi.nlm.nih.gov
Schizophrenia: Overview and Treatment Options - PMC Back to Top Skip to main content NIH
NLM Logo Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation …
NLM Logo Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation …
Mortality gap for people with bipolar disorder and schizophrenia: UK-based cohort study 2000–2014
BackgroundBipolar disorder and schizophrenia are associated with increased mortality
relative to the general population. There is an international emphasis on decreasing this …
relative to the general population. There is an international emphasis on decreasing this …
[HTML][HTML] Almost all antipsychotics result in weight gain: a meta-analysis
M Bak, A Fransen, J Janssen, J van Os, M Drukker - PloS one, 2014 - journals.plos.org
Introduction Antipsychotics (AP) induce weight gain. However, reviews and meta-analyses
generally are restricted to second generation antipsychotics (SGA) and do not stratify for …
generally are restricted to second generation antipsychotics (SGA) and do not stratify for …
[HTML][HTML] Increased mortality in schizophrenia due to cardiovascular disease–a non-systematic review of epidemiology, possible causes, and interventions
PA Ringen, JA Engh, AB Birkenaes, I Dieset… - Frontiers in …, 2014 - frontiersin.org
Frontiers | Increased Mortality in Schizophrenia Due to Cardiovascular Disease – A Non-Systematic
Review of Epidemiology, Possible Causes, and Interventions Skip to main content Top bar …
Review of Epidemiology, Possible Causes, and Interventions Skip to main content Top bar …
Clozapine and long-term mortality risk in patients with schizophrenia: a systematic review and meta-analysis of studies lasting 1.1–12.5 years
JM Vermeulen, G van Rooijen… - Schizophrenia …, 2019 - academic.oup.com
Introduction Patients with schizophrenia have an elevated mortality risk compared to the
general population, with cardiovascular-related deaths being the leading cause. The role of …
general population, with cardiovascular-related deaths being the leading cause. The role of …
Schizophrenia,“Just the Facts” 5. Treatment and prevention Past, present, and future
R Tandon, HA Nasrallah, MS Keshavan - Schizophrenia research, 2010 - Elsevier
The introduction of second-generation antipsychotics and cognitive therapies for
schizophrenia over the past two decades generated considerable optimism about …
schizophrenia over the past two decades generated considerable optimism about …
Excess mortality from mental, neurological and substance use disorders in the Global Burden of Disease Study 2010
Aims. Mortality-associated burden of disease estimates from the Global Burden of Disease
2010 (GBD 2010) may erroneously lead to the interpretation that premature death in people …
2010 (GBD 2010) may erroneously lead to the interpretation that premature death in people …
Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology
TRE Barnes… - Journal of …, 2011 - journals.sagepub.com
These guidelines from the British Association for Psychopharmacology address the scope
and targets of pharmacological treatment for schizophrenia. A consensus meeting, involving …
and targets of pharmacological treatment for schizophrenia. A consensus meeting, involving …